Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2013

Open Access 01-12-2013 | Research article

Oral intake of phenylbutyrate with or without vitamin D3upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis

Authors: Akhirunnesa Mily, Rokeya Sultana Rekha, S M Mostafa Kamal, Evana Akhtar, Protim Sarker, Zeaur Rahim, Gudmundur H Gudmundsson, Birgitta Agerberth, Rubhana Raqib

Published in: BMC Pulmonary Medicine | Issue 1/2013

Login to get access

Abstract

Background

We earlier showed that 4-phenylbutyrate (PB) can induce cathelicidin LL-37 expression synergistically with 1,25-dihydroxyvitamin D3 in a lung epithelial cell line. We aimed to evaluate a therapeutic dose of PB alone or in combination with vitamin D3 for induction of LL-37 expression in immune cells and enhancement of antimycobacterial activity in monocyte-derived macrophages (MDM).

Methods

Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I), 500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D3 {5000 IU once daily (o.d.)}, PB (500 mg b.d.) (Group-IV) or vitamin D3 (5000 IU o.d.) (Group-V), given orally for 4 days. Blood was collected on day-0, day-4 and day-8; plasma was separated, peripheral blood mononuclear cells (PBMC), non-adherent lymphocytes (NAL) and MDM were cultured. LL-37 transcript in cells and peptide concentrations in supernatant were determined by qPCR and ELISA, respectively. In plasma, 25-hydorxyvitamin D3 levels were determined by ELISA. MDM-mediated killing of Mycobacterium tuberculosis (Mtb) (H37Rv) was performed by conventional culture method.

Results

MDM from Group-II had increased concentration of LL-37 peptide and transcript at day-4, while Group-I showed increased transcript at day-4 and day-8 compared to day-0 (p < 0.05). Both Group-I and -II exhibited higher levels of transcript on day-4 compared to Group-III and Group-V (p < 0.035). Increased induction of peptide was observed in lymphocytes from Group-II on day-4 compared to Group-I and Group-IV (p < 0.05), while Group-IV showed increased levels on day-8 compared to Group-I and Group-III (p < 0.04). Intracellular killing of Mtb on day-4 was significantly increased compared to day-0 in Group-I, -II and -V (p < 0.05).

Conclusion

The results demonstrate that 500 mg b.d. PB with 5000 IU o.d. vitamin D3 is the optimal dose for the induction of LL-37 in macrophages and lymphocytes and intracellular killing of Mtb by macrophages. Hence, this dose has potential application in the treatment of TB and is now being used in a clinical trial of adults with active pulmonary TB (NCT01580007).
Appendix
Available only for authorised users
Literature
1.
Smith PE, Moss AR: Tuberculosis: pathogenesis, protection, and control, epidemiology of tuberculosis. Epidemiol Tuberc. 1994, 1: 47-60.
2.
Parsons LM, Driscoll JR, Taber HW, Salfinger M: Drug resistance in tuberculosis. Infect Dis Clin North Am. 1997, 11 (4): 905-928. 10.1016/S0891-5520(05)70397-4.CrossRefPubMed
3.
Bradford WZ, Daley CL: Multiple drug-resistant tuberculosis. Infect Dis Clin North Am. 1998, 12 (1): 157-172. 10.1016/S0891-5520(05)70415-3.CrossRefPubMed
4.
Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH: HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010, 181 (1): 80-86. 10.1164/rccm.200907-0989OC.CrossRefPubMed
5.
Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse IM, Andersen PL, Glerup H, Sodemann M: Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2009, 179 (9): 843-850. 10.1164/rccm.200804-567OC.CrossRefPubMed
6.
Martins M: Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K + transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)–a novel, patentable approach to limit the emergence of XDR-TB. Recent Pat Antiinfect Drug Discov. 2011, 6 (2): 110-117. 10.2174/157489111796064524.CrossRefPubMed
7.
Zasloff M: Antimicrobial peptides of multicellular organisms. Nature. 2002, 415 (6870): 389-395. 10.1038/415389a.CrossRefPubMed
8.
Zaiou M, Gallo RL: Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med (Berl). 2002, 80 (9): 549-561. 10.1007/s00109-002-0350-6.CrossRef
9.
Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003, 3 (9): 710-720. 10.1038/nri1180.CrossRefPubMed
10.
Kai-Larsen Y, Agerberth B: The role of the multifunctional peptide LL-37 in host defense. Front Biosci. 2008, 13: 3760-3767.CrossRefPubMed
11.
Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006, 311 (5768): 1770-1773. 10.1126/science.1123933.CrossRefPubMed
12.
Liu PT, Stenger S, Tang DH, Modlin RL: Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol. 2007, 179 (4): 2060-2063.CrossRefPubMed
13.
Salahuddin N, Ali F, Hasan Z, Rao N, Aqeel M, Mahmood F: Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT study [supplementary cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis. BMC Infect Dis. 2013, 13: 22-10.1186/1471-2334-13-22.CrossRefPubMedPubMedCentral
14.
Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ: A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med. 2007, 176 (2): 208-213. 10.1164/rccm.200701-007OC.CrossRefPubMed
15.
Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC, Darmalingam M, Davidson RN: High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011, 377 (9761): 242-250. 10.1016/S0140-6736(10)61889-2.CrossRefPubMedPubMedCentral
16.
Nnoaham KE, Clarke A: Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2008, 37 (1): 113-119.CrossRefPubMed
17.
Raqib R, Sarker P, Bergman P, Ara G, Lindh M, Sack DA, Nasirul Islam KM, Gudmundsson GH, Andersson J, Agerberth B: Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A. 2006, 103 (24): 9178-9183. 10.1073/pnas.0602888103.CrossRefPubMedPubMedCentral
18.
Islam D, Bandholtz L, Nilsson J, Wigzell H, Christensson B, Agerberth B, Gudmundsson G: Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat Med. 2001, 7 (2): 180-185. 10.1038/84627.CrossRefPubMed
19.
Bergman P, Johansson L, Asp V, Plant L, Gudmundsson GH, Jonsson AB, Agerberth B: Neisseria gonorrhoeae downregulates expression of the human antimicrobial peptide LL-37. Cell Microbiol. 2005, 7 (7): 1009-1017. 10.1111/j.1462-5822.2005.00530.x.CrossRefPubMed
20.
Sarker P, Ahmed S, Tiash S, Rekha RS, Stromberg R, Andersson J, Bergman P, Gudmundsson GH, Agerberth B, Raqib R: Phenylbutyrate counteracts Shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy. PLoS One. 2011, 6 (6): e20637-10.1371/journal.pone.0020637.CrossRefPubMedPubMedCentral
21.
Steinmann J, Halldorsson S, Agerberth B, Gudmundsson GH: Phenylbutyrate induces antimicrobial peptide expression. Antimicrob Agents Chemother. 2009, 53 (12): 5127-5133. 10.1128/AAC.00818-09.CrossRefPubMedPubMedCentral
22.
Yoshio H, Tollin M, Gudmundsson GH, Lagercrantz H, Jornvall H, Marchini G, Agerberth B: Antimicrobial polypeptides of human vernix caseosa and amniotic fluid: implications for newborn innate defense. Pediatr Res. 2003, 53 (2): 211-216. 10.1203/00006450-200302000-00003.CrossRefPubMed
23.
Edfeldt K, Liu PT, Chun R, Fabri M, Schenk M, Wheelwright M, Keegan C, Krutzik SR, Adams JS, Hewison M: T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci U S A. 2010, 107 (52): 22593-22598. 10.1073/pnas.1011624108.CrossRefPubMedPubMedCentral
24.
Soliman MM, Ahmed MM, Salah-Eldin AE, Abdel-Aal AA: Butyrate regulates leptin expression through different signaling pathways in adipocytes. J Vet Sci. 2011, 12 (4): 319-323. 10.4142/jvs.2011.12.4.319.CrossRefPubMedPubMedCentral
25.
de Haan JB, Gevers W, Parker MI: Effects of sodium butyrate on the synthesis and methylation of DNA in normal cells and their transformed counterparts. Cancer Res. 1986, 46 (2): 713-716.PubMed
26.
Soliman M, Kimura K, Ahmed M, Yamaji D, Matsushita Y, Okamatsu-Ogura Y, Makondo K, Saito M: Inverse regulation of leptin mRNA expression by short- and long-chain fatty acids in cultured bovine adipocytes. Domest Anim Endocrinol. 2007, 33 (4): 400-409. 10.1016/j.domaniend.2006.08.005.CrossRefPubMed
27.
Kin NW, Chen Y, Stefanov EK, Gallo RL, Kearney JF: Cathelin-related antimicrobial peptide differentially regulates T- and B-cell function. Eur J Immunol. 2011, 41 (10): 3006-3016. 10.1002/eji.201141606.CrossRefPubMedPubMedCentral
28.
Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jornvall H, Wigzell H, Gudmundsson GH: The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood. 2000, 96 (9): 3086-3093.PubMed
29.
Ottenhoff TH, Kaufmann SH: Vaccines against tuberculosis: where are we and where do we need to go?. PLoS Pathog. 2012, 8 (5): e1002607-10.1371/journal.ppat.1002607.CrossRefPubMedPubMedCentral
30.
Campbell GR, Spector SA: Autophagy induction by vitamin D inhibits both Mycobacterium tuberculosis and human immunodeficiency virus type 1. Autophagy. 2012, 8 (10): 1523-1525.CrossRefPubMedPubMedCentral
31.
Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, Lee ZW, Lee SH, Kim JM, Jo EK: Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe. 2009, 6 (3): 231-243. 10.1016/j.chom.2009.08.004.CrossRefPubMed
32.
Lee JS, Lee GM: Effect of sodium butyrate on autophagy and apoptosis in Chinese hamster ovary cells. Biotechnol Prog. 2012, 28 (2): 349-357. 10.1002/btpr.1512.CrossRefPubMed
Metadata
Title
Oral intake of phenylbutyrate with or without vitamin D3upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis
Authors
Akhirunnesa Mily
Rokeya Sultana Rekha
S M Mostafa Kamal
Evana Akhtar
Protim Sarker
Zeaur Rahim
Gudmundur H Gudmundsson
Birgitta Agerberth
Rubhana Raqib
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2013
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-13-23

Other articles of this Issue 1/2013

BMC Pulmonary Medicine 1/2013 Go to the issue

Research article

Serum levels of N–terminal proB–type natriuretic peptide in mechanically ventilated critically ill patients – relation to tidal volume size and development of acute respiratory distress syndrome

Research article

Bone marrow-derived progenitor cells in end-stage lung disease patients

Research article

Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD

Research article

Long-term CPAP treatment partially improves the link between cardiac vagal influence and delta sleep

Research article

A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan

Research article

Exhaled nitric oxide is related to atopy, but not asthma in adolescents with bronchiolitis in infancy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits